Jennifer Anne Doudna

Born: 1964

Country of Birth: USA

Nationality: USA

Ethnicity: White

Pomona College, BA Biochemistry 1985; Harvard University MA & PhD 1989 Biological Chemistry & Molecular Pharmacology; University of Colorado-Boulder Postdoctoral Scholar in Biomedical Science 1991-1994

Field of Study: Biochemistry; Molecular Biology;CRISPR; RNA Biology; gene editing

Institution/Corporation: University of Colorado, Boulder; Yale University; University of California, Berkeley; Gladstone Institutes; University of California, San Francisco

Degrees & Memberships: Member: Howard Hughes Medical Investigator (1997); National Academy of Sciences (2002); American Academy of Arts & Sciences ( 2003); Institute of Medicine of the National Academies (2010); President & Chair, Board of Innovative Genomes Institute; faculty scientist Lawrence Berkeley National Laboratory; Senior Investigator Gladstone Institute; National Academy of Inventors (2014); American Academy of Microbiology (2015); Foreign Member The Royal Society (ForMemRS, 2016); Pontifical Academy of Sciences (2021)

Awards: NSF Alan T. Waterman Award (2000); Jacob Heskel Gabbay Award (2014)(with Emmanuelle Charpentier & Feng Zhang); Breakthrough Prize in Life Sciences (2015)(w/Charpentier); Princess of Asturias Award (2015)(w/Charpentier); Tang Prize in Biopharmaceutical Science (2016)(w/Charpentier & Zhang); Japan Prize (2017)(w/charpentier); Kavli Prize in Nanoscience (2018)(w/Charpentier & Virginijus Siksnys); Wolf Prize in Medicine (2020)(w/Charpentier); Nobel Prize in Chemistry (2020)(w/Charpentier);Packard Foundation Fellow Award (1996); 2008, american Association for the Advancement of Science Fellow Award; 2015 Gruber Prize in Genetics (w/Charpentier); 2016, Canada Gairdner International Award (w/Charpentier, Zhang, Philippe Horvath & Rudolphe Barrangou); 2015, named 1 of Time 100 Most Influential People; 1996, Beckman Young Investigators Award; 2001, Eli Lilly Award in Biological Chemistry, American Chemical Society; 2016, Heinekin Prize for Biochemistry & Biophysics; 2017, Albany Medical Center Prize (w/Charpentier, Lucian Maraffini, Zhang & Francisco Mojica); 2018, NAS Award in Chemical Sciences; 2018, Pearl Meister Greengard Prize, Rockefeller University; 2018, Medal of Honor, American Cancer Society; 2019, Harvey Prize, Technion/Israel (w/Charpentier & Zhang); 2019, LIU Che Woo Prize for Welfare Benefit; 2017, Golden Plate Award, American Academy of Achievement; 2020, Guggenheim Fellowship; 2021 Award for Excellence in Molecular Diagnostics, Association for Molecular Pathology; 2014, Dr. Paul Janssen Award for Biomedical Research (w/Charpentier); 2015, Time 100:Pioneers (w/Charpentier); 2016, Paul Ehrlich & Ludwig Darmstaeder Prize (w/Charpentier); 2016, HFSP Nakasone Award (w/Charpentier); 2017, BBVA Foundation Frontiers of Knowledge Award (w/Charpentier & Mojica)

Achievements: CRISPR-Cas9 Gene Editing; founder Editas Medicine; her research focuses on RNA; developed genome editing tools & anti-CRISPR agents; 2012, she & Charpentier were the 1st to propose CRISPR-Cas9 could be used for programmable editing of genomes; has crystallized ribozymes; 2011, co-founded Carabou Biosciences; co-founded Intellia Therapuetics & Scribe Therapeutics; discovered that the hepatitus C virus utilizes an unusual strategy to synthesize viral proteins; 2017, co-founded Mammouth Biosciences;